Deerfield finances pioneer in 3D printing for pharmaceuticals

Published: 29-Jan-2016
Manufacturing Drug Delivery Research & Development Finance Pharmaceutical Dosage Forms

Proceeds from the financing will allow Aprecia to launch SPRITAM, the first 3D printed medicine approved by the US Food and Drug Administration


Deerfield Management Company has invested US$30m to lead a $35m financing in Aprecia Pharmaceuticals.

Proceeds from this financing will allow Aprecia to launch SPRITAM, the first 3D printed medicine approved by the US Food and Drug Administration, as well as accelerate the development of additional 3D printed drug formulations using Aprecia's novel 3DP technology platform.

Aprecia is a speciality pharmaceutical company using its proprietary 3D printing technology platform to develop and manufacture pharmaceuticals. The company's ZipDose formulation platform enables the production of rapidly dissolving dosage forms that may exceed the formulation limits of existing fast-melt technologies. SPRITAM is an oral fast-melt form of levetiracetam for epilepsy.

‘Based on extensive market research conducted by the Deerfield Institute, we believe there is a substantial population of epilepsy patients, particularly children, who are not well served by existing formulations and will benefit from SPRITAM and the other epilepsy drugs in Aprecia's pipeline,’ said Jonathan Leff, Partner at Deerfield.

‘We are very pleased to join with the Aprecia team to advance the commercialisation of important new therapies based on the company's unique 3D printing technology,’ he added.

‘We are excited to have Deerfield as our partner in the launch of SPRITAM. Deerfield has demonstrated tremendous knowledge of the field as well as creativity and flexibility in structuring the financing. With its desire to advance healthcare and address unmet patient needs, we believe Deerfield is an ideal partner for Aprecia,’ said Don Wetherhold, CEO of Aprecia.

See more

You may also like

Manufacturing

Aprecia and Battelle partner on 3D printing

Read more
The collaboration will aim to advance 3D printing equipment from clinical supply through commercial scale, while increasing manufacturing throughput and efficiency at every level

Trending Articles

  1. Pfizer gains European Commission approval for haemophilia A and B drug, Hympavzi The subcutaneous therapeutic is the first and only anti-tissue factor pathway inhibitor approved for the treatment of haemophilia A or B, and is available in an auto-injector format
  2. Dual-chamber packaging systems as a simplification factor in the supply chain Dual-chamber packaging solutions could represent a new frontier also to package parenteral drugs, simplifying the supply chain through reconstitution, potentially making logistics more flexible and efficient, says Cecilia Bassi, Product Manager at Bormioli Pharma
  3. Sanofi invests €40m into biopharmaceutical manufacturing at its Lyon Gerland site The pharma giant has expanded its French monoclonal antibody production capabilities, while also dedicating €25m to the development of a second-gen polyclonal antibody
  4. BioPharmaSpec expands its biopharma discovery and preclinical capabilities with three new facilities The contract research organisation (CRO) has expanded its European presence with three facilities, which are catered for biopharmaceutical drug discovery and preclinical characterisation

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Manufacturing

Aprecia and Battelle partner on 3D printing

The collaboration will aim to advance 3D printing equipment from clinical supply through commercial scale, while increasing manufacturing throughput and efficiency at every level
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

A new dimension in drug manufacturing

The FDA approval of the first 3D printed drug for public use signals changes ahead for the pharma manufacturing sector
You need to be a subscriber to read this article.
Click here to find out more.
Drug Delivery

Designer pills and smart capsules that can deliver

Oral delivery of drugs remains a preferred route, and innovation in this field is at its most creative. Dr Sarah Houlton looks at some of the interesting options under development
Drug Delivery

US FDA approves first 3D printed drug product

Aprecia uses the proprietary ZipDose technology to manufacture a treatment to control seizures in epilepsy
Manufacturing

Samsung Biologics bags $668 manufacturing deal with European pharmaceutical company

The CDMO will be responsible for the manufacture of the client's biopharmaceuticals until December 2031
Manufacturing

CDMO GBI Biomanufacturing expands US drug product services with aseptic fill/finish capabilities

Its Florida site will now be able to support biopharma clients from clinical trials to commercialisation with a dual manual/automated fill/finish approach
Manufacturing

Sartorius Stedim Biotech supports bioprocess development with new Innovation Centre

The Massachusetts, US-based Centre for Bioprocess Innovation is a collaborative space designed to develop and optimise biomanufacturing processes
Subscribe now